New surgical options, novel therapeutics and the merging of technologies will continue to define the future of glaucoma management, according to George A. Cioffi, MD, keynote speaker at the virtual Glaucoma 360 New Horizons Forum.
“We need implantable or injectable sustained-release drugs, we need better, longer-lasting agents, and we’ve had some of those,” Cioffi said.
For example, long-acting latanoprostene bunod and netarsudil products have been developed.
“We even just recently got the first injectable. It took longer than most of us thought it would, but ... going
Uncategorized